Bacterial Conjunctivitis
📧 Sign up to get email alerts when something new happens for Bacterial Conjunctivitis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2009-09-29Clinical Trial Update: AL-15469A for the Treatment of Bacterial Conjunctivitis [Phase 3]
A Phase 3 clinical trial evaluating AL-15469A for bacterial conjunctivitis has completed.
-
CLINICAL_TRIALS trial_result · 2009-08-13Clinical Trial Update: Clinical and Microbial Efficacy of ISV403 in Bacterial Conjunctivitis [Phase 2]
Phase 2 trial evaluated the clinical and microbial efficacy of ISV403 in bacterial conjunctivitis. The study is completed with results poste…
-
CLINICAL_TRIALS trial_result · 2009-08-13Clinical Trial Update: A Study to Investigate the Safety and Efficacy of BOL-303224 in the Treatment of Bacterial Conjunctivitis [Phase 3]
Phase 3 study evaluating the safety and efficacy of BOL-303224 for acute bacterial conjunctivitis has completed, with results posted in 2009…
-
CLINICAL_TRIALS trial_result · 2009-08-13Clinical Trial Update: A Study to Determine if 0.6% ISV-403 is Safe and Effective in the Treatment of Bacterial Conjunctivitis. [Phase 3]
A Phase 3 trial evaluated the safety and effectiveness of 0.6% ISV-403 for acute bacterial conjunctivitis. The study completed and results w…
-
FDA approval · 2009-05-28FDA Approved: BESIVANCE — Original Application (Bausch & Lomb Americas Inc.)
The FDA approved Besivance (besifloxacin) in its original application for the treatment of bacterial conjunctivitis.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2009-02-13FDA Approved: TOBRADEX ST — Original Application (Harrow Eye, LLC)
The FDA approved TOBRADEX ST (tobramycin/dexamethasone) from Harrow Eye, LLC via an original NDA for treating ocular infections and inflamma…
-
FDA approval · 2008-11-06FDA Approved: TOBRAMYCIN AND DEXAMETHASONE — Supplemental Application (Bausch & Lomb Incorporated)
FDA approved a supplemental application for Tobramycin and Dexamethasone from Bausch & Lomb, approving changes to the already-approved ophth…
-
FDA approval · 2008-09-15FDA Approved: NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE — Supplemental Application (Sandoz Inc.)
FDA approved a supplemental application for NEOMYCIN AND POLYMYXIN B SULFATES AND DEXAMETHASONE (Sandoz) to support a generic version of thi…
-
CLINICAL_TRIALS trial_result · 2007-11-29Clinical Trial Update: Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis [Phase 2, Phase 3]
This update reports results from phase 2 and phase 3 trials evaluating the efficacy of levofloxacin 0.5% ophthalmic solution administered th…
-
FDA approval · 2007-04-27FDA Approved: AZASITE — Original Application (Thea Pharma Inc.)
FDA approved the original application for AZASITE (azithromycin monohydrate) for the treatment of bacterial conjunctivitis; the product is m…
-
FDA approval · 2006-08-07FDA Approved: LOTEPREDNOL ETABONATE AND TOBRAMYCIN — Supplemental Application (Bausch & Lomb Americas Inc.)
The FDA approved a supplemental application for the ophthalmic combination Loteprednol etabonate and tobramycin (brand Zylet) from Bausch & …
-
CLINICAL_TRIALS trial_result · 2006-07-27Clinical Trial Update: Efficacy and Safety of T1225 1.5% Versus Tobramycin 0.3 % in the Treatment of Purulent Bacterial Conjunctivitis [Phase 3]
Phase 3 trial comparing T1225 1.5% to Tobramycin 0.3% for purulent bacterial conjunctivitis has completed, evaluating efficacy and safety.
-
CLINICAL_TRIALS trial_result · 2006-07-27Clinical Trial Update: Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1 and 1.5% in 48 Healthy Volunteers [Phase 1]
Phase 1 trial evaluating safety and ocular pharmacokinetics after a single drop of T1225 at 0.5%, 1%, and 1.5% in 48 healthy volunteers.
-
CLINICAL_TRIALS trial_result · 2006-07-27Clinical Trial Update: Ocular Tolerance, Safety and Ocular Pharmacokinetics After 1 Drop of T1225 0.5, 1.0, 1.5% in 48 Healthy Volunteers [Phase 1]
Phase 1 trial assessing ocular tolerance, safety, and ocular pharmacokinetics after a single drop of T1225 at 0.5%, 1.0%, or 1.5% in 48 heal…